Drugs / Fluoroethyl-L-tyrosine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07456878 | Jan → Dec 2026 expected | pituitary gland adenoma | Mayo Clinic | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fluoroethyl-L-tyrosine | “after intravenous administration of 5 mCi ± 0.5 mCi of Fluoroethyl-L-tyrosine (\[18F\]FET)” NCT07456878 ↗ |
| Known as | \[18F\]FET | “after intravenous administration of 5 mCi ± 0.5 mCi of Fluoroethyl-L-tyrosine (\[18F\]FET)” NCT07456878 ↗ |
| Modality | Diagnostic / imaging agent | “evaluate the diagnostic role and clinical efficacy of investigational FET-PET/MRI” NCT07456878 ↗ |
| Route | Intravenous | “after intravenous administration of 5 mCi ± 0.5 mCi of Fluoroethyl-L-tyrosine (\[18F\]FET)” NCT07456878 ↗ |